Choroidal nonperfusion with significant subretinal exudation after PDT of predominantly classic CNV: an OCT and FFA study.
OBJECTIVE
Despite the increasing use of antivascular endothelial growth factors (anti-VEGF), photodynamic therapy (PDT) with Verteporfin is still considered the gold standard treatment of subfoveal and juxtafoveal classic choroidal neovascularization (CNV).


METHODS
Case report.


RESULTS
The authors report a case of a 72-year-old man who developed choroidal nonperfusion and significant subretinal fluid formation with associated severe visual loss following PDT of predominantly classic juxtafoveal CNV.


CONCLUSIONS
Although reported separately, these two complications have not been previously reported to occur in association after PDT treatment of classic CNV and may represent exaggeration of normal events occurring after PDT.
Jalil
Assad
A
Manchester Royal Eye Hospital, Manchester, UK.
Mercieca
Karl
K
Chaudhry
Nadia L
NL
Stanga
Paulo E
PE
D000368:Aged; D001284:Atrophy; D002829:Choroid / Q000098:blood supply*; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D005122:Exudates and Transudates; D005451:Fluorescein Angiography; D006801:Humans; D007208:Indocyanine Green; D007511:Ischemia / Q000175:diagnosis / Q000209:etiology*; D008297:Male; D009887:Ophthalmoscopy; D010778:Photochemotherapy / Q000009:adverse effects*; D017319:Photosensitizing Agents / Q000009:adverse effects; D011166:Porphyrins / Q000009:adverse effects; D012164:Retinal Diseases / Q000175:diagnosis / Q000209:etiology*; D055213:Retinal Pigment Epithelium / Q000473:pathology; D041623:Tomography, Optical Coherence; D000077362:Verteporfin; D014792:Visual Acuity
D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin; D007208:Indocyanine Green